Clinical Trial Update: Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating persistence of MR3 in relapsed chronic myeloid leukemia after a second stop of TKI therapy. The current status of th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Snippet

Sponsor: Amsterdam UMC, location VUmc | Conditions: CML, Relapsed | Phase 2 | Status: UNKNOWN